Arcturus Therapeutics Holdings Inc. (ARCT): Price and Financial Metrics

Arcturus Therapeutics Holdings Inc. (ARCT): $30.43

2.11 (-6.48%)

POWR Rating

Component Grades

Momentum

C

Stability

F

Sentiment

Quality

C

Add ARCT to Watchlist
Sign Up

ARCT Price/Volume Stats

Current price $30.43 52-week high $43.81
Prev. close $32.54 52-week low $17.52
Day low $30.02 Volume 405,000
Day high $32.30 Avg. volume 451,962
50-day MA $35.86 Dividend yield N/A
200-day MA $29.99 Market Cap 819.02M

ARCT Stock Price Chart Interactive Chart >


Arcturus Therapeutics Holdings Inc. (ARCT) Company Bio


Arcturus Therapeutics Ltd a biopharmaceutical company, focuses on the development and commercialization of oral drug candidates. The company was founded in 2008 and is based in Tel Aviv, Israel.


ARCT Latest News Stream


Event/Time News Detail
Loading, please wait...

ARCT Latest Social Stream


Loading social stream, please wait...

View Full ARCT Social Stream

Latest ARCT News From Around the Web

Below are the latest news stories about ARCTURUS THERAPEUTICS HOLDINGS INC that investors may wish to consider to help them evaluate ARCT as an investment opportunity.

CSL and Arcturus Therapeutics’ ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster

KING OF PRUSSIA, Pa. & SAN DIEGO, December 21, 2023--Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) and Arcturus Therapeutics (Nasdaq: ARCT) today announced the publication in Lancet Infectious Diseases of a Phase 3 study showing that a booster dose of ARCT-154, a novel, self-amplifying messenger RNA (sa-mRNA) vaccine, elicited a numerically higher immune response (meeting the non-inferiority criteria) against the original Wuhan-Hu-1 virus strain, and a superior immune response against O

Yahoo | December 21, 2023

7 Undervalued Biotech Stocks That are Flying Under the Clinical Radar

With so many innovative firms skyrocketing this year, astute investors seeking compelling discounts may want to turn their attention to undervalued biotech picks.

Josh Enomoto on InvestorPlace | December 17, 2023

3 Biotech Stocks With Promising Pipelines and Big Growth Potential in 2024

These biotech stocks with promising pipelines are showing some major promise and growth potential for the new year.

Chandler Capital on InvestorPlace | December 14, 2023

Is There An Opportunity With Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) 46% Undervaluation?

Key Insights The projected fair value for Arcturus Therapeutics Holdings is US$47.95 based on 2 Stage Free Cash Flow to...

Yahoo | December 14, 2023

12 Best Healthcare Stocks For the Long-Term

In this piece, we will take a look at the 12 best healthcare stocks for the long term. If you want to skip our overview of the healthcare industry, then you can take a look at 5 Best Healthcare Stocks For the Long-Term. The healthcare industry is one of the biggest industries in the world. […]

Yahoo | December 8, 2023

Read More 'ARCT' Stories Here

ARCT Price Returns

1-mo -16.19%
3-mo N/A
6-mo 35.43%
1-year 10.37%
3-year -23.00%
5-year 290.13%
YTD -3.49%
2023 85.91%
2022 -54.17%
2021 -14.68%
2020 299.08%
2019 139.96%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!